More clinical lessons from the FIELD study

Cardiovascular Drugs and Therapy

Volumn 23, Issue 3, 2009, Pages 235-241

  Fazio, Sergio ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Fenofibrate; FIELD; Retinopathy; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ALBUMINURIA; AMPUTATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; LOW LEVEL LASER THERAPY; LUNG EMBOLISM; METABOLIC SYNDROME X; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; TRAUMATIC AMPUTATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; PROCETOFEN;

EID: 67649128495     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-008-6160-5     Document Type: Review

References (42)

1. KGMM Alberti P Zimmet J Shaw 2007 International Diabetes Federation: a consensus on type 2 diabetes prevention Diabet Med. 24 451 463 (Pubitemid 46669328)
2. J Stamler O Vaccaro JD Neaton 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care. 16 434 444 (Pubitemid 23046633)
3. H Miettinen S Lehto V Salomaa 1998 Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group Diabetes Care. 21 69 75
4. R Huxley F Barzi M Woodward 2006 Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies BMJ. 332 73 78
5. B Isomaa P Almgren T Tuomi 2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care. 24 683 689 (Pubitemid 32893993)
6. E Chiquette R Chilton 2002 Cardiovascular disease: much more aggressive in patients with type 2 diabetes Curr Atheroscler Rep. 4 134 142
7. LL Lipscombe JE Hux 2007 Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study Lancet. 369 750 756 (Pubitemid 46321630)
8. EW Gregg Q Gu YJ Cheng 2007 Mortality trends in men and women with diabetes, 1971-2000 Ann Intern Med. 147 149 155 (Pubitemid 351664594)
9. TJ Hoerger JE Segel EW Gregg JB Saaddine 2008 Is glycemic control improving in U.S. adults? Diabetes Care. 31 81 86
10. G Imperatore BL Cadwell L Geiss 2004 Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000 Am J Epidemiol. 160 531 539 (Pubitemid 39215629)
11. CS Fox S Coady PD Sorlie 2007 Increasing cardiovascular disease burden due to diabetes mellitus The Framingham Heart Study Circulation. 115 1544 1550 (Pubitemid 46648639)
12. The United States Renal Data System. USRDS Annual Data Report. Bethesda, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2006. Available from http://www.usrds.org/atlas.htm. Accessed 28 Jan 2008.
13. American Diabetes Association 2008 Standards of medical care in diabetes-2008 Diabetes Care 31(suppl) S12 54
14. L Ryden E Standl M Bartnik Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) 2007 Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary Eur Heart J 28 88 136
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection 2002 Evaluation, and treatment of high blood cholesterol in adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report Circulation 106 3143 3421
16. JB Buse HN Ginsberg GL Bakris 2007 Primary prevention of cardiovascular diseases in people with diabetes mellitus. A Scientific Statement from the American Heart Association and the American Diabetes Association Circulation. 115 114 126 (Pubitemid 46058619)
17. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837 853
18. UKPDS report number 38 1998 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes BMJ 317 703 713
19. CJ Packard 2003 Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein Biochem Soc Trans. 31 1066 1069 (Pubitemid 37305047)
20. FM Sacks H Campos 2003 Low-density lipoprotein size and cardiovascular disease: a reappraisal J Clin Endocrinol Metab. 88 4525 4532
21. Cholesterol Treatment Trialist's (CTT) Collaborators 2008 Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 117 125
22. C Baigent A Keech PM Kearney 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet. 366 1267 1278
23. J Shepherd P Barter R Carmena 2006 Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. The Treating to New Targets (TNT) study Diabetes Care. 29 1220 1226 (Pubitemid 44125913)
24. P Deedwania P Barter R Carmena 2006 Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets Study Lancet. 368 919 928 (Pubitemid 44331360)
25. RS Birjmohun BA Hutten JJP Kastelein 2005 Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials J Am Coll Cardiol. 45 185 197 (Pubitemid 40094724)
26. MJ Chapman 2003 Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives Atherosclerosis. 171 1 13 (Pubitemid 37474095)
27. HB Rubins SJ Robins D Collins 2002 Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT) Arch Intern Med 162 2597 2604 (Pubitemid 35453499)
28. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-10.
29. A Keech RJ Simes P Barter FIELD Study Investigators 2005 Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial Lancet 366 1849 1861
30. A Keech J Simes P Barter 2006 Correction to the FIELD Study report Lancet. 368 1415 (Pubitemid 44573457)
31. Heart Protection Study Collaborative Group 2003 MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2005 2016
32. Scott R, O'Brien R, Fulcher G, et al. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 2008; published online November 4, 2008.
33. A Tenenbaum M Motro EZ Fisman 2005 Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome Arch Intern Med. 165 1154 1160 (Pubitemid 40720740)
34. D Burgess D Hunt LP Li 2007 Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Circulation. 116 II-838
35. AC Keech P Mitchell PA Summanen 2007 Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD Study): a randomised controlled trial Lancet. 370 1687 1697 (Pubitemid 350100775)
36. JC Ansquer C Foucher S Rattier 2005 Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis. 45 485 493 (Pubitemid 40341327)
37. MH Davidson A Armani JM McKenney TA Jacobson 2007 Safety considerations with fibrate therapy Am J Cardiol 99 3C 18C
38. AA Alsheikh-Ali JT Kuvin RH Karas 2004 Risk of adverse events with fibrates Am J Cardiol. 94 935 938 (Pubitemid 39349562)
39. PH Jones MH Davidson 2005 Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin Am J Cardiol. 95 120 122 (Pubitemid 40051126)
40. T Prueksaritanont C Tang Y Qiu 2002 Effects of fibrates on metabolism of statins in human hepatocytes Drug Metab Dispos. 30 1280 1287 (Pubitemid 35265837)
41. A Corsini S Bellosta MH Davidson 2005 Pharmacokinetic interactions between statins and fibrates Am J Cardiol 96 44K 9K
42. ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes trial: design and methods. Am J Cardiol 2007;99:21i-33i.